Anatomy of an optimized antibody. Blue indicates sites for potential engineering.
XmAb® technologies are a suite of proprietary antibody Fc domains and antibody engineering tools that enable the creation, with Xencor technology alone, of humanized therapeutic antibody candidates with significantly enhanced potency, half-life, affinity and ease of production or provide entirely novel immuno-modulatory mechanisms of action. Fc domains are a modular and reusable suite of antibody components we developed by identifying and engineering antibody Fc regions for select amino acid changes. We created these capabilities using our PDA® computational amino acid sequence design tools.
High ADCC Variant Technology – Enhancing Fc Effector Function
XmAb® antibody technology is helping Xencor fill the substantial demand for structural and functional optimization of monoclonal antibodies as cytotoxic agents. Although hailed as “magic bullets”, the ability of antibodies to destroy targeted tumor cells is suboptimal. Using XmAb® engineered Fc domains, we are giving antibodies high antibody-dependent cellular cytotoxicity (ADCC), or more tumor killing power, by greatly improving their capacity to recruit the immune system against cancer cells and selectively engaging cytotoxic immune receptors.
Xtend™ Technology – Enhanced Half-life Antibodies
We have engineered Fc domains to significantly enhance the in vivo half-life of monoclonal antibodies, which has the potential to enable new dosing routes, enhance patient convenience and reduce overall cost of antibody therapies.
γRIIb (CD32b) Technology – Immuno-modulation
We have created a novel immuno-modulatory platform by engineering Fc domains for selective high affinity binding to FcγRIIb (CD32b), a receptor on B cells and other immune cells with dominant inhibitory activity. The CD32b pathway has never been therapeutically exploited and applied to high affinity antibodies targeting immune cells. It offers the potential for new antibody therapies that are highly specific, safer and potent at blocking autoimmune disease processes.
Fv Optimization Technology – Enhanced Affinity
We combine our unique approach for optimizing Fc domains with proprietary Fv engineering tools that create high-affinity, humanized antibodies, giving Xencor the capability to address all aspects of antibody candidate discovery.
Ease of Production
Our structure-based approach also creates highly soluble and readily expressed antibodies, enabling us to circumvent obstacles that can often delay or halt antibody development. Physical and production characteristics are crucial for advancing candidates to the clinic but are usually not addressed by older antibody design methods.